Wedbush Issues Optimistic Outlook for ZNTL Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Research analysts at Wedbush increased their Q2 2025 earnings per share estimates for Zentalis Pharmaceuticals in a research report issued on Thursday, May 15th. Wedbush analyst R. Driscoll now expects that the company will post earnings of ($0.57) per share for the quarter, up from their previous estimate of ($0.66). Wedbush currently has a “Neutral” rating and a $4.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($2.19) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($1.42) EPS, FY2028 earnings at ($0.73) EPS and FY2029 earnings at ($0.17) EPS.

Several other equities research analysts have also recently weighed in on the company. UBS Group reduced their price objective on Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Wells Fargo & Company reduced their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 30th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Thursday. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $8.24.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock opened at $1.26 on Monday. Zentalis Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $13.00. The stock’s 50-day moving average price is $1.44 and its 200-day moving average price is $2.33. The stock has a market capitalization of $90.66 million, a price-to-earnings ratio of -0.51 and a beta of 1.81.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.67).

Insider Activity

In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers bought 21,000 shares of the business’s stock in a transaction dated Wednesday, April 30th. The shares were purchased at an average price of $1.40 per share, with a total value of $29,400.00. Following the completion of the purchase, the director now owns 281,192 shares in the company, valued at $393,668.80. This represents a 8.07% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 1.90% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

A number of large investors have recently modified their holdings of ZNTL. Barclays PLC boosted its holdings in shares of Zentalis Pharmaceuticals by 18.5% in the third quarter. Barclays PLC now owns 75,395 shares of the company’s stock valued at $277,000 after purchasing an additional 11,748 shares during the period. SG Americas Securities LLC lifted its holdings in Zentalis Pharmaceuticals by 115.6% during the fourth quarter. SG Americas Securities LLC now owns 56,389 shares of the company’s stock worth $171,000 after buying an additional 30,240 shares during the period. Savant Capital LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter valued at $72,000. Ieq Capital LLC purchased a new position in Zentalis Pharmaceuticals in the 4th quarter worth $46,000. Finally, Anfield Capital Management LLC raised its position in Zentalis Pharmaceuticals by 100.0% during the 4th quarter. Anfield Capital Management LLC now owns 129,318 shares of the company’s stock worth $392,000 after buying an additional 64,659 shares during the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.